

# Mohammed Tanjimur Rahman Mbbs

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7080331/publications.pdf>

Version: 2024-02-01

28  
papers

932  
citations

535685

17  
h-index

563245

28  
g-index

28  
all docs

28  
docs citations

28  
times ranked

1975  
citing authors

#	ARTICLE	IF	CITATIONS
1	The P387 thrombospondin-4 variant promotes accumulation of macrophages in atherosclerotic lesions. <i>FASEB Journal</i> , 2020, 34, 11529-11545.	0.2	1
2	Effects of thrombospondin-4 on pro-inflammatory phenotype differentiation and apoptosis in macrophages. <i>Cell Death and Disease</i> , 2020, 11, 53.	2.7	29
3	Ectopic Otoconin 90 expression in triple negative breast cancer cell lines is associated with metastasis functions. <i>PLoS ONE</i> , 2019, 14, e0211737.	1.1	7
4	IFN- $\gamma$ , IL-17A, or zonulin rapidly increase the permeability of the blood-brain and small intestinal epithelial barriers: Relevance for neuro-inflammatory diseases. <i>Biochemical and Biophysical Research Communications</i> , 2018, 507, 274-279.	1.0	107
5	Nucleus accumbens-1/GADD45GIP1 axis mediates cisplatin resistance through cellular senescence in ovarian cancer. <i>Oncology Letters</i> , 2017, 13, 4713-4719.	0.8	6
6	CCNE1 amplification is associated with aggressive potential in endometrioid endometrial carcinomas. <i>International Journal of Oncology</i> , 2016, 48, 506-516.	1.4	43
7	Fatty Acid Synthase Is a Potential Therapeutic Target in Estrogen Receptor-/Progesterone Receptor-Positive Endometrioid Endometrial Cancer. <i>Oncology</i> , 2013, 84, 166-173.	0.9	25
8	Clinicopathologic analysis of loss of AT-rich interactive domain 1A expression in endometrial cancer. <i>Human Pathology</i> , 2013, 44, 103-109.	1.1	26
9	A Case of Stage III c Ovarian Clear Cell Carcinoma: The Role for Predictive Biomarkers and Targeted Therapies. <i>International Journal of Molecular Sciences</i> , 2013, 14, 6067-6073.	1.8	7
10	Is ATP7B a Predictive Marker in Patients With Ovarian Carcinoma Treated With Platinum-Taxane Combination Chemotherapy?. <i>International Journal of Gynecological Cancer</i> , 2013, 23, 60-64.	1.2	3
11	KRAS and MAPK1 Gene Amplification in Type II Ovarian Carcinomas. <i>International Journal of Molecular Sciences</i> , 2013, 14, 13748-13762.	1.8	24
12	Notch3 Overexpression as Potential Therapeutic Target in Advanced Stage Chemoresistant Ovarian Cancer. <i>American Journal of Clinical Pathology</i> , 2012, 138, 535-544.	0.4	56
13	Uterine Leiomyosarcoma Producing Granulocyte Colony Stimulating Factor. <i>International Journal of Gynecological Pathology</i> , 2012, 31, 172-177.	0.9	6
14	Loss of ARID1A expression is related to shorter progression-free survival and chemoresistance in ovarian clear cell carcinoma. <i>Modern Pathology</i> , 2012, 25, 282-288.	2.9	170
15	Frequent Loss of Tumor Suppressor ARID1A Protein Expression in Adenocarcinomas/Adenosquamous Carcinomas of the Uterine Cervix. <i>International Journal of Gynecological Cancer</i> , 2012, 22, 208-212.	1.2	22
16	Biological and clinical significance of NAC1 expression in cervical carcinomas: a comparative study between squamous cell carcinomas and adenocarcinomas/adenosquamous carcinomas. <i>Human Pathology</i> , 2012, 43, 506-519.	1.1	38
17	Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma. <i>Human Pathology</i> , 2012, 43, 2197-2206.	1.1	59
18	Fatty acid synthase expression associated with NAC1 is a potential therapeutic target in ovarian clear cell carcinomas. <i>British Journal of Cancer</i> , 2012, 107, 300-307.	2.9	29

#	ARTICLE	IF	CITATIONS
19	Sister Mary Joseph's nodule associated with rare endometrial squamous cell carcinoma. Archives of Gynecology and Obstetrics, 2012, 286, 711-715.	0.8	7
20	Prognostic and therapeutic impact of the chromosome 20q13.2 <i>ZNF217</i> locus amplification in ovarian clear cell carcinoma. Cancer, 2012, 118, 2846-2857.	2.0	51
21	EGFR gene amplification is related to adverse clinical outcomes in cervical squamous cell carcinoma, making the EGFR pathway a novel therapeutic target. British Journal of Cancer, 2011, 105, 420-427.	2.9	62
22	Microwave endometrial ablation is a highly efficacious way to emergently control life-threatening uterine hemorrhage. Archives of Gynecology and Obstetrics, 2011, 283, 1065-1068.	0.8	16
23	MKK4 acts as a potential tumor suppressor in ovarian cancer. Tumor Biology, 2011, 32, 661-670.	0.8	14
24	Loss of MKK4 expression in ovarian cancer: A potential role for the epithelial to mesenchymal transition. International Journal of Cancer, 2011, 128, 94-104.	2.3	23
25	Expression of nuclear Notch3 in cervical squamous cell carcinomas and its association with adverse clinical outcomes. Gynecologic Oncology, 2010, 117, 409-416.	0.6	43
26	Biological role and prognostic significance of NAC1 in ovarian cancer. Gynecologic Oncology, 2010, 119, 469-478.	0.6	34
27	MEK inhibition suppresses cell invasion and migration in ovarian cancers with activation of ERK1/2. Experimental and Therapeutic Medicine, 2010, 1, 591-596.	0.8	11
28	Functional and Clinicopathological Analysis of Loss of MKK4 Expression in Endometrial Cancer. Oncology, 2010, 79, 238-246.	0.9	13